A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy
A phase 3 trial testing HRS-8080 in HR-positive / HER2-negative breast cancer, now recruiting.
Overview
A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy is a phase 3 interventional study registered as NCT07354022, led by Shandong Suncadia Medicine, and recruiting when checked on 2026-09-11. Official title: A Multicenter, Open-label, Randomised Controlled Phase III Clinical Study Evaluating the Efficacy and Safety of HRS-8080 Combined With Dalpiciclib Versus Fulvestrant Combined With Dalpiciclib in Patients With Locally Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy. Planned enrolment is 912 participants (estimated). The study started in 2026-05-05 and primary completion is expected in 2028-12. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals, HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialA Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals, HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialA Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)
Shares Jiangsu Hengrui Pharmaceuticals and the tag ctgov-ingest.
- TrialA Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Shares Jiangsu Hengrui Pharmaceuticals and the tag ctgov-ingest.
- TrialA Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Shares Jiangsu Hengrui Pharmaceuticals and the tag ctgov-ingest.
- TrialA Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
Shares Jiangsu Hengrui Pharmaceuticals and the tag ctgov-ingest.
- TrialA Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC
Shares Jiangsu Hengrui Pharmaceuticals and the tag ctgov-ingest.
- TrialA Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer
Shares Jiangsu Hengrui Pharmaceuticals and the tag ctgov-ingest.